Trials / Withdrawn
WithdrawnNCT01478555
A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease
A Dose-Finding Study To Compare The Safety, Tolerability, And Efficacy Of Differing Dosing Regimens Of ISV-101 (Bromfenac In DuraSite® Ophthalmic Solution) To Vehicle And DuraSite Alone In Dry Eye Disease Volunteers
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-101 (Bromfenac in DuraSite® ophthalmic solution) compared to Vehicle and DuraSite alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISV 101 | Bromfenac in DuraSite |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2018-07-01
- Completion
- 2019-01-01
- First posted
- 2011-11-23
- Last updated
- 2021-11-19
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01478555. Inclusion in this directory is not an endorsement.